Patient Factors, Safety, and Long-Term Efficacy Best Inform Treatment Selection Across Hematologic Malignancies
Michael Choi, MD, expands on significant advancements and treatment considerations in hematologic malignancies.
Stay updated with breaking news from Science Summit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Michael Choi, MD, expands on significant advancements and treatment considerations in hematologic malignancies.
Petros Grivas, MD, PhD, discusses the role of single-agent and combination PARP inhibitor regimens in prostate cancer, as well as the importance of genetic testing in this setting, the role of adjuvant regimens in resected renal cell carcinoma, and more.
Michael Choi, MD, discusses several key considerations for the treatment of chronic lymphocytic leukemia from his presentation at a recent OncLive® State of the Science Summit™ on hematologic malignancies.
David R. Wise, MD, PhD, discusses his presentation from an OncLive® State of the Science Summit™ on prostate cancer, during where he discussed the treatment of patients with metastatic castration-resistant prostate cancer.
Eirwen M. Miller, MD, spotlights updated data within the endometrial, cervical, and ovarian cancer spaces following the ESMO Congress 2023 and the 2023 ASCO Annual Meeting, focusing on how these updates continue to shift clinical practice and advance care.